Engineered immune cells take on lupus in first human test
NCT ID NCT06333483
First seen Jan 08, 2026 · Last updated Jun 23, 2026 · Updated 25 times
Summary
This early-phase trial is testing a one-time treatment called obecabtagene autoleucel (obe-cel) for people with severe lupus that hasn't improved with standard treatments. Obe-cel is made by taking a patient's own immune cells, engineering them to target and attack faulty B cells, and giving them back after a short course of chemotherapy. The main goals are to see if the treatment is safe and tolerable, and to get an early look at whether it can put lupus into remission. Only 18 participants will be enrolled.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SYSTEMIC LUPUS ERYTHEMATOSUS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Addenbrookes Hospital
RECRUITINGCambridge, CB2 0QQ, United Kingdom
Contact Email: •••••@•••••
-
Great Ormond Street Hospital
RECRUITINGLondon, WC1N 3JH, United Kingdom
Contact Email: •••••@•••••
-
Hospital Universitari Vall Hebrón
RECRUITINGBarcelona, 08035, Spain
Contact Email: •••••@•••••
-
Hospital Universitari i Politecnic La Fe
RECRUITINGValencia, 106046026, Spain
Contact Email: •••••@•••••
-
Manchester Royal Infirmary, Manchester University NHS Foundation Trust,
RECRUITINGManchester, M13 9WL, United Kingdom
Contact Email: •••••@•••••
-
University College London Hospitals NHS Foundation Trust
RECRUITINGLondon, NW1 2PG, United Kingdom
Contact Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
obecabtagene autoleucel (obe-cel), a CAR T-cell therapy made from the patient's own immune cells
What this could lead to
If it works, this could point toward a new treatment option for people with severe lupus that hasn't responded to other therapies.
What could go wrong
This is a very early Phase 1 trial with only 18 participants, so it's mainly checking safety. The treatment may not work, and there are risks like severe immune reactions or side effects from the chemotherapy used beforehand.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.